

Table E1

Laboratory Evaluation	Reference Ranges	2014	2015	2016
<b>WBC (K/mcL)</b>	4.5-13.5K/mcL	<b>2</b>	<b>4</b>	<b>2.4</b>
<b>Hgb (gm/dL)</b>	12-16 gm/dL	11	12	13.9
<b>PLT (K/mcL)</b>	135-466K/mcL	<b>92</b>	178	<b>91</b>
<b>Neutrophils</b>	40-62%	<b>15</b>	40	<b>31</b>
<b>Lymphocytes</b>	15-45%	<b>63</b>	44	<b>52</b>
<b>Monocytes</b>	0-8%	<b>16</b>	<b>11</b>	<b>9</b>
<b>Eosinophils</b>	0-5%	4	4	8
<b>Basophils</b>	0-1%	1	1	0
<b>ANC (mcL)</b>	1.8-8K/mcL	<b>0.3</b>	1.6	<b>0.74</b>
<b>ALC (mcL)</b>	1.5-6.5K/mcL	1.2	1.76	1.25
<b>Reticulocytes</b>	0.5-1.5%	1.9	2.8	2
<b>Direct Coombs</b>	-	+	+	-
<b>Anti-neutrophil Abs</b>	-	+	+	+
<b>Anti-PLT Abs</b>	-	+	+	+
<b>Anti-Class I/II Abs</b>		-	+	+
<b>Lymphocyte subsets</b>				
<b>CD3</b>	52-78% 800-3500 cells/mcL	77 % 1309	77% 1243	78% 1092
<b>CD4</b>	25-48% 400-2100 cells/mcL	44% 694	43% 689	48% 663
<b>CD8</b>	9-35% 200-1200 cells/mcL	32% 545	29% 469	25% 349
<b>CD19</b>	(8-24%) 200-600 cells/mcL	21% 358	20% 324	20% 276
<b>CD16/56</b>	6-27% 70-1200	<b>1%</b> <b>17</b>	<b>2%</b> <b>38</b>	<b>1%</b> <b>19</b>
<b>CD4/CD8</b>	1.0-3.6	1.3	1.5	1.9
<b>FOXP3+Tregs</b>	55-81%	68	58	61
<b>CD4+25+127 low Tregs</b>	4.2-9.9% of CD4+	4.4	4.4	4.4
<b>TCRV11/VA24</b>	>=0.01%	0.06		
<b>CD4+CCR6+CD45RA-*</b>	10.7-27% of CD4+	20.1	19.3	
<b>CCR6+CD45RA-IL-17A+</b>	1.2-4.6% of * cells	<b>5.6</b>	3.6	
<b>ALPS Markers</b>				
<b>IL-10</b>	<=7 pg/mL	5	1	6
<b>IL-18</b>	89-540 pg/mL	657	499	614
<b>Vit B12</b>	193-986 pg/mL	774	788	775
<b>Fas-apoptosis cell loss</b>	55-95%	81		97
<b>TCRαβ-DNT cells*</b>	> 2% of lymphocytes*	<b>2.6</b>	<b>1.9</b>	<b>2.6</b>
<b>B220 TCRαβ-DNT cells*</b>	> 60% of DNT cells*	19	22	32
<b>CD3+CD25+HLA/DR ratio*</b>	< 1*	1	1.1	1
<b>CD27+ B cells*</b>	< 15% of B cells*	<b>8</b>	<b>8</b>	<b>9</b>
<b>IgG</b>	600-1500 mg/dL	1150	On IVIG	On IVIG
<b>IgM</b>	60-263 mg/dL	<b>54</b>	71	166
<b>IgA</b>	68-378 mg/dL	200	213	234
<b>IgE</b>	2-214 mg/dL	3	-	3
<b>B-cell Panel</b>				
<b>CD19+ B cells</b>	8- 24 %	15	18	
<b>CD19+CD27-CD21-IgM++</b>	0.5- 2.8 %	<b>6.7</b>	<b>5.7</b>	
<b>CD19+CD27-</b>	61- 83 %	<b>87</b>	<b>89</b>	
<b>CD19+CD27-IgM+IgD+</b>	53- 79 %	<b>83</b>	<b>85</b>	
<b>CD19+CD27-IgM+IgD+</b>	80- 97 % of CD27-	95	95	
<b>CD19+CD27-CD21-CD38-</b>	0.3- 2.3 %	<b>4.4</b>	<b>5</b>	
<b>CD19+CD27+</b>	17- 39 %	<b>13</b>	<b>11</b>	
<b>CD19+CD27+IgM+IgD+</b>	8- 22 %	10	9	
<b>CD19+CD27+IgM+IgD+</b>	30-76 % of CD27+	<b>79</b>	<b>78</b>	
<b>CD19+CD27+IgM-IgD-</b>	2.3- 18.2 %	<b>1.8</b>	<b>1.7</b>	
<b>CD19+CD27+IgM-IgD-</b>	14-44 % of CD27+	14	15	

Table E1

**Table E1. A. Immunological Evaluation at Referral and Follow-up Visits**  
Bold values represent abnormal values.



\* Parameters specific for flow cytometry based ALPS panel. Reference values indicate positive ALPS score for each parameter.

# Mother-mutant asymptomatic

HC

Father

Patient







Gated on  
CD4<sup>+</sup> T cells

Ctrl





Patient

Father




Mother-carrier



Gated on  
T<sub>FH</sub> cells  
(CXCR5+PD1+)



Gated on  
T<sub>FH</sub> cells  
(CXCR5+PD1+)



Ctrl  
Patient

